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Improving treatment outcomes for leprosy
in Pernambuco, Brazil: a qualitative study
exploring the experiences and perceptions
of retreatment patients and their carers
Divya Khanna1* , Gilles de Wildt2, Luiz Antonio Miranda de Souza Duarte Filho3, Mitali Bajaj1, Jo Freda Lai1,
Esme Gardiner1, Andrea Maia Fernandes de Araújo Fonseca4, Antje Lindenmeyer5 and Patrícia Sammarco Rosa6
Abstract
Background: Brazil has a high leprosy burden and poor treatment outcomes (TOs), manifesting in high relapse
rates. Pernambuco, an impoverished Brazilian state suffering notable geographical health inequalities, has
‘hyperendemic’ leprosy. Although current literature identifies barriers and facilitators influencing leprosy treatment
compliance, inadequate investigation exists on other factors influencing TOs, including carers’ roles and psycho-
dermatological impact. This qualitative study explores experiences and perceptions of leprosy patients and their
carers in Pernambuco, Brazil; to identify location-specific factors influencing TOs, and consequently inform future
management.
Methods: 27, semi-structured, in-depth interviews were conducted with 14 patients and 13 carers. Participants
were recruited using maximum variation and snowball sampling from three clinics in Petrolina, Pernambuco.
Transcripts and field notes from both participant groups were separately analysed using conventional thematic and
deviant case analysis. The University of Birmingham Internal Research Ethics Committee and Instituto Lauro de
Souza Lima provided ethical approval.
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Results: Two homologous sets of four, primary, interdependent themes influencing leprosy TOs emerged: ‘personal
factors’; ‘external factors’; ‘clinical factors’; and ‘the healthcare professional (HCP)-patient-carer relationship’. Poor
participant knowledge and lack of symptomatic relief caused patients to distrust treatment. However, because
participants thought HCP-led interventions were vital for optimal TOs, patients were effectively persuaded to adhere
to pharmaceutical treatments. High standard patient and population education facilitated treatment engagement
by encouraging evidence-based medicine belief, and dispelling health myths and stigma. Healthcare, on occasions,
was perceived as disorganised, particularly in resource-scarce rural areas, and for those with mental health needs.
Participants additionally experienced incorrect/delayed diagnoses and poor contact tracing. Leprosy’s negative
socio-economic impact on employment – together with stigma, dependency and changing relationships – caused
altered senses of identity, negatively impacting TOs. Better dialogue between patients, HCPs and carers facilitated
individualised patient support.
Conclusion: This study highlights the importance of: effective evidence-based leprosy education; communication
between HCPs, patients and carers; state-funded support; and healthcare resource distribution. These findings, if
prioritised on governmental scales, provide the valuable insight needed to inform location-specific management
strategies, and consequently improve TOs. Future research should evaluate the effectiveness of these
implementations. Failure to address these findings will hinder regional elimination efforts.
Keywords: Leprosy, Patient, Carer, Experiences, Perceptions, Qualitative, Brazil
Background
Leprosy is a chronic, highly stigmatised, neglected trop-
ical disease, caused by Mycobacterium leprae, with der-
matological, neurological and ophthalmic complications
[1–3]. While leprosy’s transmission risk is low (with only
2–5% of those exposed becoming symptomatic), its slow
progression poses permanent disability risks [2]. The
World Health Organisation (WHO) has been instrumen-
tal in global leprosy elimination campaigns, through
their endorsement of a freely available, antimicrobial-
based ‘multidrug therapy’ (MDT) for patients of endemic
countries [4]. Since 1981, over 16 million patients have
been cured globally through these WHO efforts [5–7].
However, despite MDT easing leprosy’s global burden
notably, the infection remains endemic in several low-
and middle-income countries worldwide [8].
In 2018, Brazil, a middle-income South American na-
tion, reported the second highest leprosy incidence glo-
bally (after India and Indonesia); responsible for 13.7%
of worldwide cases [8, 9]. Brazil’s leprosy incidence rose
by 14% between 2015 and 2018, despite initially declin-
ing post-2009, indicating a recently worsening endemic
[8]. Further scaling the problem, in 2018, Brazil also re-
ported the second highest number of both ‘grade two
disabilities’ (visible deformities/severe visual impairment
secondary to leprosy) and ‘retreatment cases’ (patients
re-diagnosed with leprosy after receiving treatment pre-
viously) worldwide [8, 10].
Pernambuco, a state in North-East (NE) Brazil where
27.17% of all households live in poverty, has ‘hyperen-
demic’ leprosy status. Healthcare access in Pernambuco
is ‘poor’, due to geographical inequalities present in Bra-
zil’s state-funded, primary care focussed healthcare
system, and high costs associated with better resourced
private healthcare [10–17]. In 2010, Pernambuco had al-
most double the national leprosy prevalence (3.01/10,
000 inhabitants, compared to 1.62/10,000 nationally),
cure rates 3% lower than national rates, and the highest
percentage of MDT-discontinuing patients countrywide
(8.2%) [18, 19].
These statistics indicate poor treatment outcomes
(TOs) in Pernambuco, particularly in terms of cure,
symptom improvement, quality of life, coexisting ill-
ness, and healthcare service discharge [18]. The inter-
dependent implications of poor TOs go beyond mere
statistics. Firstly, poor TOs act alongside the stigma
and negative religious connotations associated with
leprosy in Brazil, further impacting patient quality of
life, mental and physical health, and socioeconomic
status [20–22]. Furthermore, while antimicrobial re-
sistance (AMR) currently causes only 5% of Brazil’s
retreatment cases, poor TOs encourage this percent-
age, and the global AMR concern, to rise [23–25].
Poor TOs in Pernambuco also increase patient infec-
tiousness; promoting disease transmission and hinder-
ing regional WHO elimination efforts [10].
As for any disease, improving leprosy TOs in Pernam-
buco requires a location-specific insight into the popula-
tion’s experiences, perceptions and beliefs of leprosy and
its treatment [26]. Literature on other diseases shows
carer support has a symbiotic relationship with TOs;
therefore, their views should be appreciated alongside
those of patients [27–31]. To gauge the depth of evi-
dence currently available, a MEDLINE literature search
for English and Portuguese language literature, or litera-
ture with English and Portuguese language abstracts,
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was conducted. Because experiences and perceptions re-
quire probing and prove difficult to quantify, only quali-
tative literature was searched [29]. The following search
terms were used: ‘leprosy AND therapy’ AND ‘patient
OR family OR carer’ AND ‘attitude OR perception OR
patient dropout OR noncompliance OR relapse’. Results
were limited to those published post-2009, as this year
limit coincides with the time frames of the most recently
published WHO global leprosy statistical analysis [8].
Reference lists of identified papers were searched for
‘grey’ literature, which was not previously located
through the systematic literature searches.
Six studies were identified [27, 32–36], of which one
was found when searching for ‘grey’ literature [36]. One
systematic review (SR) of 20 qualitative studies published
between 2005 and 2013 identified numerous facilitators
and barriers of treatment compliance, which they
grouped into two categories to form a theoretical frame-
work: ‘personal factors’ (sub-divided into ‘life quality’,
‘socio-economic factors’, and ‘cultural needs’) and ‘med-
ical factors’ (sub-divided into ‘treatment regimen’ and
‘health services’) [32]. However, the five further studies
found facilitators and barriers of treatment compliance
that are neither mentioned in, nor can be grouped into,
the SR’s theoretical framework, including concepts sur-
rounding: quality of knowledge on leprosy; importance
for one’s own health; health beliefs; personality and be-
haviour; and experiences of stigma [27, 33–36]. This in-
dicates that the SR’s theoretical framework is not
comprehensive.
There are further limitations to these studies beyond
the lack of a comprehensive theoretical framework.
Some studies used qualitative questionnaires, which re-
stricted the depth and breadth of participant responses
[27, 32, 35]. Others recognised that their findings are
not transferable, and therefore proposed the need for
further, location-specific research, in order to effectively
inform local healthcare policy-making [27, 32–34, 36].
Brazil, a nation with unique socio-economic profiles,
cultural attitudes, political climates and healthcare deliv-
ery structures which vary considerably by state and mu-
nicipality, would benefit from this, as factors such as: the
quality of leprosy-related knowledge; side effect impact;
health beliefs; and religion have only been explored in
non-Brazilian participants [18, 32]. Additionally, findings
of the last published Brazilian study may no longer be
relevant, as viewpoints may have shifted with the re-
cently increasing national leprosy incidence [8, 32]. The
research-deprived NE region would also benefit from
location-specific research, as the geographical density of
leprosy research in Brazil is not distributed proportion-
ally to the geographical density of disease; with most
studies conducted in the less affected, wealthier South-
East region [37]. No literature exists on carers, despite
their impact on TOs documented in studies of other dis-
eases [28, 31, 38]; or on retreatment patients, who form
an information-rich subgroup of leprosy patients with
first-hand experiences of disease relapse, and therefore
poor TOs [39]. Finally, apart from one Portuguese study
which focussed on stigma [36], the present literature fo-
cuses primarily on facilitators and barriers of medication
compliance. Novel research is therefore required, as
medication compliance and stigma are only two of the
factors influencing TOs [31, 38]. These evidence gaps
collectively justify the WHO’s decision to make investi-
gation into factors influencing leprosy TOs their re-
search priority [23].
Overall, the literature search indicates poor under-
standing on the barriers and facilitators of leprosy TOs
in Pernambuco. This study, part of a wider study titled,
[40] aims to address the evidence gap alongside the
WHO research priority, by exploring retreatment pa-
tients’ and carers’ experiences, perceptions and beliefs of
leprosy and its treatment in Pernambuco.
Methods
Design
A qualitative, in-depth interview study design, employing
semi-structured topic guides, was used for a holistic,
profound exploration of the study aim. While quantita-
tive methods have more rigour and yield generalizable,
statistically significant numeric data, this qualitative de-
sign was best suited to gather rich data on the complex,
multifaceted, sensitive topics being explored [41–45].
Focus groups presented issues of confidentiality, unequal
participant input, and peer influence, and therefore were
not chosen [44].
Setting
This study was conducted in Petrolina: a densely popu-
lated, agricultural city of Pernambuco, NE Brazil, with a
2010 population of 293,962 [46]. Petrolina was chosen
due to similar and therefore representative demograph-
ics to Pernambuco [18, 46]. Three, free, state-funded
clinics, all part of the Sistema Único de Saúde (SUS),
Brazil’s publicly funded healthcare system, were used to
identify patients: Unidade Básica de Saúde Miguel de
Lima Durando, Unidade Básica de Saúde Gildevania de
Oliveira Silva, and Serviço de Infectologia de Petrolina.
The two former sites were rurally-located, while the lat-
ter was urban.
Sampling and recruitment
DK, AF, LD and PR used maximum variation purposive
sampling to intentionally identify information-rich pa-
tients from clinic registers [47]. Snowball sampling en-
abled interviewees to identify further study participants,
and was the primary method to identify carers [48].
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Participants were selected based on the following eligi-
bility criteria: a) leprosy retreatment patient, or such a
patient’s carer; b) residing in Petrolina; c) aged over 18
years old; and d) fluent in Portuguese or English. Partici-
pants were excluded if they: a) had illnesses affecting
their ability to conduct a meaningful interview; b) could
not provide informed consent; or c) felt interviewing
would cause significant harm/stress to them. After each
interview, participant demographics (including occupa-
tion, age, gender, socioeconomic status and urban/rural
residence) were discussed amongst the study team, to
identify demographics missing from the sample. To fa-
cilitate maximum variation and increase validity, individ-
uals with the identified missing demographics were
sought in further sampling, [47] until data saturation
was achieved. For comparative purposes, balanced num-
bers of a) patients and carers, and b) urban and rural
participants were recruited.
Recruitment was undertaken in February and March
2020. DK, AF, LD and PR approached eligible partici-
pants and explained the study aims and design using
participant information sheets. Participants were made
aware that partaking was voluntary and would not im-
pact healthcare professional (HCP) care provisions.
Data collection
Semi-structured, one-to-one, face-to-face interviews
were guided by separate topic guides, formulated
uniquely for the purpose of this study, for patients and
carers (Tables 1 and 2) [see Additional File 1]. The topic
guides incorporated factors influencing TOs in previous
literature; factors the study supervisors deemed import-
ant; and Patton’s six interview questions (behaviour/ex-
perience, opinion/belief, feelings, knowledge, sensory,
background/demographic) [49]. The semi-structured
format permitted flexibility for the discussion of ideas
unanticipated by study personnel (for new theme
synthesis), whilst enabling interviewers to re-orientate
discussions if participants digressed [50, 51]. Pilot inter-
views, consisting of open, semi-structured questions,
were conducted on Day 1 to overcome translational dif-
ficulties and allow topic guide familiarisation across the
study team. The topic guides were iteratively revised be-
tween interviews using the constant comparative
method; incorporating questions on unanticipated ideas
until no new ideas surfaced, indicating data saturation
[52].
Interviews were conducted in Portuguese by PR and
LD. Although it is appreciated that using one interviewer
is preferable, PR, LD and DK compared questioning
styles and discussed issues arising from pilot interviews
to ensure interviewing technique similarity.
Informed written/thumbprint consent was obtained
from all participants before interviewing, which took
place in private consultation rooms at the three afore-
mentioned clinics, or at participants’ homes. Interviews
were audio-recorded on password-protected, encrypted
devices, with DK writing down field observations imme-
diately after interviews. LD transcribed interviews into
English. A random sample of three transcripts were
checked by an independent translator to gauge transla-
tion quality. Minimal, grammatical changes were made.
Participation withdrawal was permitted at any point up
to 48 h post-interviewing, to reduce negative impact on
the constant comparative method [50, 52].
Data analysis
Analysing interview data ensued alongside its collection
iteratively using the constant comparative method, [52]
which determined the point of data saturation.
Provisional themes emerging from this were discussed
with PR and LD to gain a more culturally astute insight,
minimising risks of cross-cultural bias [53]. Conven-
tional thematic and deviant case analyses were
Table 1 Topic guide for patient participants
Topic Subtopics
Questions exploring personal factors ▪ Knowledge about leprosy and treatment
▪ Beliefs about leprosy transmission and cure
▪ Experiences of restarting treatment
▪ Importance of health
▪ Leprosy manifestations
▪ Medication side effects
▪ Medication compliance and coping mechanisms
▪ Psychological impact
Questions exploring external factors ▪ Employment and future aspirations
▪ Experiences of diagnosis
▪ Access to healthcare
▪ Importance of HCP
▪ Contact tracing
Questions exploring support network ▪ Sharing diagnosis with community
▪ Stigma
▪ Family and social circle
▪ Religion
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conducted by DK after interviewing to produce accurate
reflections of the participant voice [54–57]. These ana-
lyses were suitable for the study due to absent pre-
existing theoretical frameworks, and their ability to yield
rich narratives on the most pertinent themes influencing
TO [55]. Braun and Clarke’s six step guide, Saldana’s
two step cycle and NVivo 12 software were used to sys-
tematically approach data coding [56, 57].
JL and MB triangulated 10% of transcripts to introduce
unbiased, fresh perspectives on coding, and increase val-
idity [58]. Triangulated data was compared with DK’s
coding to increase credibility, [58] with discrepancies
and unexpected findings facilitating theme revision.
Themes were reviewed by the study personnel to ensure
interpretations represented the yielded data, thereby re-
ducing bias associated with a single analyst. Member val-
idation was not practiced due to study time constraints.
DK appreciated the impact of researcher bias throughout
analysis as part of a reflexive approach [59]. Findings
were reported with consideration of the Consolidated
Criteria for Reporting Qualitative Research [60].
Ethical considerations
The study was approved by the Instituto Lauro de Souza
Lima ethics committee, Brazil on 11/12/2019 (3.746.443),
and the University of Birmingham Internal Research Eth-
ics Committee, United Kingdom on the 06/01/2020
(IREC2019/1636664). Data will be stored for ten years ac-
cording to the University of Birmingham data protection
policy and the Data Protection Act, 2018 [61, 62].
Results
28 interviews were conducted in February and March
2020. Tables 3 and 4 summarise patient and carer
Table 2 Topic guide for carer participants
Topic Subtopics
Questions exploring personal factors ▪ Knowledge about leprosy and treatment
▪ Beliefs about leprosy transmission and cure
▪ Experiences of patient restarting treatment
▪ Importance of health
▪ Leprosy manifestations in the patient
▪ Medication side effects and coping mechanisms
▪ Medication compliance
▪ Psychological impact on self and carer
Questions exploring external factors ▪ Experiences of carer role
▪ Employment and future aspirations
▪ Access to healthcare
▪ Importance of HCP
▪ Contact tracing
Questions exploring support network ▪ Sharing diagnosis with community
▪ Stigma
▪ Family and social circle
▪ Religion
Table 3 Summary of patient participants’ demographics
Identifier Clinic type Age bracket Education Gender Job Number of people in household Consent type
001 Urban 35 ≤ x < 45 Incomplete elementary school Female Unemployed 4 Written
002 Urban 45 ≤ x < 55 Incomplete elementary school Male Unemployed 5 Thumbprint
004 Urban 65 ≤ x < 75 No formal education Male Farmer 3 Thumbprint
005 Urban 35 ≤ x < 45 Completed elementary school Male Public agent 2 Written
009 Urban 35 ≤ x < 45 Incomplete elementary school Male Self-employed 9 Written
010 Urban 35 ≤ x < 45 Completed elementary school Male Farmer 3 Written
012 Rural 75 ≤ x < 85 Incomplete elementary school Female Housewife 1 Written
016 Rural 25 ≤ x < 35 Completed high school Female Housemaid 5 Written
018 Rural 45 ≤ x < 55 Completed elementary school Male Self-employed 3 Written
019 Rural 35 ≤ x < 45 Completed elementary school Female Unemployed 5 Written
021 Rural 35 ≤ x < 45 University education Female Unemployed 2 Written
022 Rural 65 ≤ x < 75 Completed elementary school Male Retired 2 Written
026 Urban 45 ≤ x < 55 Completed high school Female Housewife 5 Written
027 Urban 55 ≤ x < 65 Incomplete elementary school Male Unemployed 9 Written
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participant demographics, respectively. One interview
(011 – Patient) was discarded due to poor recording
quality, leaving 27 usable interviews in total. Interviews
lasted on average for 20 min, ranging in length from
seven (013 – Carer) to 46 min (026 – Patient). All carers
were family members of patients. No participants with-
drew from the study.
Separate analyses of the two groups produced two
homologous sets of four interdependent themes: 1)
‘personal factors’; 2) ‘external factors’; 3) ‘clinical fac-
tors’; and 4) ‘the HCP-patient-carer relationship’. Ta-
bles 5 and 6 summarise coding for patient and carer
participant groups, respectively. Due to maximum
variation sampling, the frequency of a specific view
is not indicative of the view’s importance, but rather
its popularity and presence within the study sample
[47].
Quotes have been selected to aid understanding of
themes and subthemes, and illustrate similarities and dif-
ferences in the sample’s opinion.
Theme 1: personal factors
This theme explores factors depending solely on the par-
ticipant, and is subdivided into three subthemes: ‘know-
ledge and information quality’; ‘health beliefs’; and
‘psychological impact and character’.
Subtheme a: knowledge and information quality
13 patients and 11 carers exhibited limited overall un-
derstanding of leprosy, with a sizeable proportion unable
to provide even simple explanations about the disease,
and almost all unable to identify the cause of leprosy
transmission.
Researcher: ‘What do you know about leprosy’?
Participant: ‘I have virtually no knowledge’ (018 –
Patient)
Researcher: ‘How do you think you get the disease?’
Participant: ‘I never shower with hot water and
then suddenly with cold, or after eating, because I
thought that’s what causes leprosy. I don’t know how
I got it.’ (018 – Patient)
Participant: ‘Because of cockroaches.’ (019 – Pa-
tient)
Participant: ‘The sun. Petrolina is hot, and [the pa-
tient] was out at midday.’ (020 – Carer)
Despite all participants either experiencing leprosy re-
lapse, or caring for a relapse patient, relapse was poorly
understood in all but one participant. Many patients and
carers did not realise that the treatment they/the patient
was receiving was a separate, second course of medica-
tions, targeting relapsed leprosy. Some patients per-
ceived health education as their HCPs’ responsibility,
and consequently blamed their poor relapse knowledge
on inadequate HCP-led education.
Researcher: ‘Do you know what relapse is?’
Participant: ‘No, sorry. Nobody at the clinic ever
told me about that.’ (009 – Patient)
Participant: ‘ … my sister-in-law said it was when
her leprosy came back.’ (017 – Carer)
Some carers had poor knowledge because they per-
ceived the patient as the primary knowledge source, and
did not use other accessible means to obtain further
Table 4 Summary of carer participants’ demographics
Identifier Clinic type Age bracket Education Gender Job Number of people in household Consent type
003 Urban 35 ≤ x < 45 Incomplete elementary school Female Housewife 7 Written
006 Urban 35 ≤ x < 45 Completed high school Male Self-employed 1 Written
007 Urban 45 ≤ x < 55 Completed elementary school Female Farmer 2 Written
008 Urban 65 ≤ x < 75 No formal education Male Retired 2 Thumbprint
013 Rural 55 ≤ x < 65 Completed elementary school Male Truck driver 5 Written
014 Rural 35 ≤ x < 45 Completed elementary school Male Mechanic 5 Written
015 Rural 55 ≤ x < 65 Incomplete elementary school Female Housewife 5 Written
017 Rural 25 ≤ x < 35 Incomplete elementary school Female Hairdresser 3 Written
020 Rural 55 ≤ x < 65 No formal education Female Housewife 2 Thumbprint
023 Rural 18 ≤ x < 25 Completed elementary school Female Unemployed 3 Written
024 Urban 55 ≤ x < 65 Incomplete elementary school Female Housewife 3 Written
025 Urban 35 ≤ x < 45 University education Female Estate agent 4 Written
028 Rural 75 ≤ x < 85 Incomplete elementary school Female Housemaid 4 Written
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information. Carers with good knowledge were proactive
and resourceful when searching for information.
Participant: ‘We are curious, but [the patient] never
told me about leprosy, so I never asked.’
Researcher: ‘Did you look online or in health centres
instead?’
Participant: ‘No.’ (013 – Carer)
Participant: ‘I like to learn more about leprosy so I
can take better care of [the patient].’ (003 – Carer)
More knowledgeable participants agreed that the
internet (for those with access) and television pro-
grammes, were useful, information-rich sources supple-
menting HCP-given knowledge between clinic visits.
Programmes dedicating airtime to Brazil’s national lep-
rosy campaign, ‘Purple January’, effectively raised public
awareness [63]. Some participants expressed the import-
ance of mass, societal education on leprosy, and alluded
to schools being an effective medium.
Participant: ‘After the appointment I searched the
internet and learnt a lot of things.’
Researcher: ‘Were you more relieved when you had
more information?’
Participant: ‘I was … when we don’t know things, it
feels like a shock, right?’ (001 – Patient)
Participant: ‘The thing about ‘Purple January’ is
that people talk about it. It is necessary for school to
teach about leprosy. These campaigns are needed.’
(026 – Patient)
Some felt that ‘word of mouth’ knowledge was less re-
liable than HCP-led education, which was greatly valued.
Table 5 Patient themes representing factors influencing leprosy TOs
Theme Facilitators of optimal TOs (frequency out of 14) Barriers to optimal TOs (frequency out of 14)
Personal factors ▪ Belief in pharmaceutical treatment (11)
▪ Use of an education source (14)
▪ Health is important to the patient (12)
▪ High standard patient knowledge on resistance or the
importance of compliance (13)
▪ Normal nature or lifestyle of participant did not change (4)
▪ Perceptions of leprosy as ‘dangerous’ or ‘contagious’ (10)
▪ Positive patient attitude, desire to be cured (13)
▪ Positive perceptions of the future, and hope in a cure (14)
▪ Psychological resilience (13)
▪ Witnessing another getting better or worse (7)
▪ Belief in traditional medicines (4)
▪ Belief medication is ‘strong’ (1)
▪ Change in the normal nature/appearance/lifestyle of
patient (12)
▪ Change in identity, feeling labelled (8)
▪ Contradicting sources of education (11)
▪ Distrust of pharmaceutical medications (8)
▪ Experience/fear of stigma and discrimination (11)
▪ Feeling helpless (8)
▪ Isolation or distance (9)
▪ Myths and misinformation (12)
▪ Other comorbidities (6)
▪ Poor quality/limited knowledge (13)
▪ Psychological impact of leprosy (14)
External factors ▪ Ease of access to treatment (10)
▪ Education to empower social circle to help the patient/reduce
stigma (9)
▪ Social circle support (emotional, nutritional, psychological,
financial) (11)
▪ Family makes sacrifices for patient (6)
▪ Holistic care by HCP team (4)
▪ Individualised, patient-led care (5)
▪ Pragmatic approach to a high standard care in a resource
scarce setting (1)
▪ Religion forms psychological support (10)
▪ Care is not holistic (5)
▪ Difficulty accessing treatment (5)
▪ Disorganised care (6)
▪ Social circle has poor/ limited knowledge of the
disease (3)
▪ Financial impact (8)
▪ Impact of illness on social circle (social/psychological/
financial) (11)
▪ Impact on aspirations for the future (5)
▪ Lack of political will to tackle leprosy (5)
▪ Living in the countryside away from services (2)
▪ Resource scarce health system (2)
▪ Impact on employment (12)
Clinical factors ▪ Contact tracing (4)
▪ Mental/physical preparation for treatment (10)
▪ Seeing/feeling improvement (10)
▪ Strategies reducing side effects (6)
▪ Late diagnosis (10)
▪ Long duration of treatment, high frequency doses (12)
▪ Comorbidities (6)
▪ Painful/distressing diagnosis (6)
▪ Progression or persistence of disease (14)
▪ Side effects of treatment (12)
HCP-patient-carer
relationship
▪ Clear information provided (diagnosis, treatment, prognosis)
(12)
▪ Good communication with HCP (9)
▪ Good quality care (6)
▪ Good, open, trusting HCP-patient-carer relationship (11)
▪ Patient feeling valued (7)
▪ Patient feels HCPs are important in their care (14)
▪ Clear information not provided on diagnosis,
treatment and prognosis (11)
▪ Poor communication/relationship with HCP (4)
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Others gained rich, anecdotal knowledge from ‘expert
patients’.
Participant: ‘People get in the way, saying this, say-
ing that. And [the patient] just gets confused. But
the clinic doctor, she studied for this, she knows what
is right and wrong.’ (023 – Carer)
Participant: ‘ … I know the woman in the waiting
room. She told me about her nerves. They became
defective. Others I know are on crutches, they can’t
walk.’ (001 – Patient)
Some participants were familiar with leprosy’s biblical
associations [63]. However, these participants agreed
that the Bible is an unreliable clinical resource.
Participant: ‘I read about leprosy, about Job, in the
Bible, where it is a chronic disease and difficult to
treat. Job had itchy wounds but there was no treat-
ment then. Now it’s different.’ (006 – Carer)
Subtheme B: health beliefs
Many perceived leprosy as dangerous or contagious,
posing threat to health. Consequently, when asked to hy-
pothesise about why some patients may have poor medi-
cation compliance, these participants felt this was due to
a poor regard for personal health.
Participant: ‘It’s contagious, and it causes numb-
ness, which is scary, because you cut yourself but
can’t feel it.’ (017 – Carer)
Participant: ‘[Patients who are non-compliant]
don’t want to be healed.’ (016 – Patient)
Carers believed their health had elevated importance,
due to their patient responsibilities.
Table 6 Carer themes representing factors influencing leprosy TOs
Theme Facilitators of optimal TOs (frequency out of 13) Barriers to optimal TOs (frequency out of 13)
Personal factors ▪ Belief in pharmaceutical treatment (10)
▪ Use of an education source (12)
▪ Health is important to the patient (7)
▪ High standard patient knowledge on resistance or the
importance of compliance (11)
▪ Normal nature or lifestyle of participant did not change (11)
▪ Perceptions of leprosy as ‘dangerous’ or ‘contagious’ (10)
▪ Positive patient attitude, desire to be cured (9)
▪ Positive perceptions of the future, and hope in a cure (13)
▪ Psychological resilience (7)
▪ Witnessing another getting better or worse (7)
▪ Belief medication is ‘strong’ (2)
▪ Change in the normal nature/appearance/lifestyle of
patient (6)
▪ Change in identity, feeling labelled (1)
▪ Contradicting sources of education (7)
▪ Distrust of pharmaceutical medications (4)
▪ Experience/ fear of stigma and discrimination (3)
▪ Feeling helpless (1)
▪ Isolation or distance (4)
▪ Myths and misinformation (8)
▪ Other comorbidities (6)
▪ Poor quality/limited knowledge (11)
▪ Psychological impact of leprosy (11)
External factors ▪ Ease of access to treatment (14)
▪ Education to empower social circle to help the patient/reduce
stigma (9)
▪ Social circle support (emotional, nutritional, psychological,
financial) (11)
▪ Family makes sacrifices for the patient (6)
▪ Holistic care by HCP team (4)
▪ Individualised, patient-led care (5)
▪ Pragmatic approach to a high standard care in a resource
scarce setting (1)
▪ Religion as a source of psychological support (10)
▪ Care is not holistic (2)
▪ Difficulty accessing treatment (4)
▪ Disorganised care (2)
▪ Financial impact (7)
▪ Impact of illness on social circle (social/psychological/
financial) (5)
▪ Impact on aspirations for the future (4)
▪ Infected family members (3)
▪ Lack of conversation about leprosy with patient (4)
▪ Lack of political will to tackle leprosy (3)
▪ Living in the countryside away from services (2)
▪ Impact on employment (6)
Clinical factors ▪ Contact tracing (3)
▪ Mental/physical preparation for treatment (9)
▪ Seeing/feeling improvement (7)
▪ Strategies reducing side effects (5)
▪ Late diagnosis (3)
▪ Long duration of treatment, high frequency doses (11)
▪ Painful/distressing diagnosis (3)
▪ Progression or persistence of disease (9)
▪ Side effects of treatment (5)
HCP-patient-carer
relationship
▪ Clear information provided (diagnosis, treatment, prognosis) (7)
▪ Good communication with HCP (6)
▪ Good quality care (7)
▪ Good, open, trusting HCP-patient-carer relationship (8)
▪ Patient feeling valued (3)
▪ Carer feels HCPs are important in their care (12)
▪ Clear information not provided on diagnosis,
treatment and prognosis (4)
▪ Patient fear or experience of stigma or discrimination
from HCP (1)
▪ Poor communication/relationship with HCP (4)
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Participant: ‘The importance of my health is every-
thing because … I dedicate myself to [the patient].’
(003 – Patient)
Most participants felt positively towards pharmaceut-
ical leprosy medications. Participants who witnessed
their own or another’s leprosy improve more commonly
expressed belief in medications.
Participant: ‘Because others have healed, why won’t
I?’ (022 – Patient)
Conversely, those yet to witness symptomatic im-
provements expressed medication distrust. Despite
this, all patients stated they were wholly compliant
with their medication regime.
Participant: ‘People stop the medicines because it takes
time to see effects. They don't believe in them because
they give up before getting better.’ (003 – Carer)
Participant: ‘I could have stopped taking the pills. But
the clinic staff kept saying, "Don't stop, otherwise it comes
back even worse.". So, I kept going.’ (010 – Patient)
Some participants, despite perceiving the medica-
tion positively, did not believe the medication was
curative. Some justified this belief by explaining that
the medication could not possibly treat severely ad-
vanced leprosy, but only alleviate symptoms.
Participant: ‘I want them to find a cure because these
remedies, they combat, but don’t cure.’ (003 – Carer)
Participant: ‘I think that at my stage, I don’t know
if I will be cured. It cures you only if you have a few
lesions.’ (027 – Patient)
Some people incorrectly believed that their medication
side effects were instead a sign of their leprosy prognosis
worsening. Numerous labelled pharmaceutical medica-
tions as ‘strong’. Some hypothesised about the effective-
ness of ‘natural’ remedies, perceived as ‘safer’.
Participant: ‘All these new problems, the medicine
isn’t working because it gave me new problems.’ (004
– Patient)
Participant: ‘I only take the medicines with food.
They are so strong, they attack the stomach, kidneys,
liver.’ (019 – Patient)
Participant: ‘Maybe certain vegetables, or maybe
herbal medicines [cure leprosy]? Would you know?’
(026 – Patient)
When asked about the advice they would give to newly
diagnosed leprosy patients, despite some participants ex-
pressing treatment disbelief, almost all stressed the im-
portance of medication compliance.
Researcher: ‘What advice would you give to a newly
diagnosed leprosy patient?’
Participant: ‘Follow the treatment correctly so it
doesn’t come back and gets better.’ (015 – Carer)
Participant: ‘It’s a delicate treatment that has to be
treated according to the doctor, so follow their ad-
vice.’ (002 – Patient)
Subtheme C: psychological impact and character
All patients and 11 carers described leprosy’s signifi-
cant psychological impact. Most described this impact
as prolonged, spanning from the time of symptom ap-
pearance and persisting indefinitely. Numerous pa-
tients felt they were no longer ‘normal’, and felt
labelled as ‘sick’. Visual leprosy manifestations affected
self-esteem, particularly in females. Participants
expressed desperation for a cure.
Participant: ‘My beautiful legs, my lovely feet, sud-
denly looked bruised … If there is no cure, I will
jump off a bridge. Because I will not live life sick
with this leprosy, like a loser. I just want to be the
same as I was.’ (018 – Patient)
Participant: ‘It did [have a psychological impact].
For two months, I wouldn’t walk with anyone, only
alone or in the night. I didn’t sleep. I didn’t realise,
but I would go to shower and still have all my
clothes on. I was upset, dejected.’ (018 – Patient)
This altered sense of identity was augmented by the
impact leprosy had on the roles and responsibilities of
participants; due to issues surrounding their ability to
work, disease transmission fears, and dependency on
others.
Researcher: ‘Do you think leprosy has a big impact
on your life?’
Participant: ‘Yes. Because I use a crutch, I have to
be with someone when I go out so they can help. It’s
annoying. The pain means I don’t sleep well, and I
Khanna et al. BMC Infectious Diseases          (2021) 21:282 Page 9 of 19
don’t have a normal day like others.’ (010 –
Patient)
Nine patients and four carers felt leprosy caused isola-
tion and distance, causing further psychological impact.
Isolation from close family members had the greatest
psychological impact.
Participant: ‘My husband was scared. He was
afraid of having sex … my daughter said, “Mom, if
you have leprosy, you have to separate.”. She sepa-
rated her glass, her plate, everything.’ (026 –
Patient)
Eleven patients, compared to only three carers, re-
ported experiences of stigma. This shows a lack of con-
versation about stigma between the two subgroups.
Several participants reporting stigma were parents of in-
fected school-going children. Leprosy’s biblical links,
widely recognised in Brazil’s large Catholic population,
[64, 65] caused experiences of shame and self-stigma.
Participant: ‘Someone I worked with asked me why
I was dark. I said it was because of leprosy treat-
ment. She stepped back. She welcomed me with a
kiss. But once she knew it was leprosy, she was quick
to leave.’ (026 – Patient)
Participant: ‘They said it is not a disease of people,
but of animals.’ (012 – Patient)
Participant: ‘My son faced stigma. Some kids found
out at school and made fun of his colour and called
him names.’ (025 – Carer)
However, almost all participants emphasised the im-
portance of a positive patient outlook. Both groups
recognised negative behaviours enhancing leprosy’s psy-
chological impact, and agreed this could be combatted
by a desire to be cured and optimistic attitudes. Many
carers spoke of keeping patients positive and motivated
towards being cured.
Participant: ‘I didn’t speak to anyone for a month.
Then my family told me being isolated is worse …
you have to talk with your loved ones.”.’ (002 –
Patient)
Participant: ‘I took the medication just how the doc-
tor said. I gave myself every chance to get better.’
(005 – Patient)
Participant: ‘He never stopped the medicine because
he just wanted to get better, get back to work. I al-
ways said, “Don’t give up!”, because otherwise there
is no point.’ (003 – Carer)
Six patients mentioned difficulties managing comor-
bidities alongside leprosy (namely aging, hypertension,
alcoholism/drug use, mental health illness, obesity and
diabetes), which resulted in new or worsening psycho-
logical symptoms. Further issues surrounding polyphar-
macy, worsening general health and poor treatment
regimen commitment caused patients ‘distress’.
Participant: ‘Leprosy made everything worse. It
made me so upset. I had to close my business. Then
I was even more upset so I started drinking cachaça*
even more, smoking marijuana … ’ (018 – Patient)
*Cachaça: a distilled spirit popular in Brazil
Participant: ‘I have diabetes. I think the treatment
made it worse. When I stopped taking the medicine,
the doctor said my diabetes got better.’ (027 –
Patient)
Theme 2: external factors
External factors describe factors outside of patient con-
trol. This theme is subdivided into three subthemes: ‘so-
cioeconomic factors’; ‘structural factors’; and ‘support
factors’.
Subtheme a: socioeconomic factors
Leprosy’s socioeconomic impact was mentioned by all
patients and most carers. Eight patients and seven
carers felt leprosy financially impacted them, as their
ability to work was restricted by symptoms and side
effects, or carer responsibilities. Wider financial impli-
cations concerned rent payments, costs travelling to
clinics, and household/family costs. One patient ex-
plained that ‘Bolsa Familia’, a Brazilian social welfare
programme providing financial aid to poor families
on conditions that their children attend school and
receive vaccinations, partly supplemented lost earn-
ings [66].
Participant: ‘I worked in grape farms. Today, I don’t
have the courage to work anymore, under the hot
sun … I am too weak. But if I don’t go to the farm,
how will I feed my children? Their lives will suffer.’
(001 – Patient)
Participant: ‘I can’t work … I have to care for [the
patient].’ (003 – Carer)
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Participant: ‘I got Bolsa Familia, because I couldn’t
work, right?’ (003 – Carer)
Younger patient participants felt leprosy impacted
them financially because their career aspirations were af-
fected, as they expected to face a lifetime of stigma in
working environments. Some felt these implications
were exacerbated by local job shortages.
Participant: ‘Who will hire a person with leprosy?
There is prejudice. I need to heal. I need to be cured.
Because I have dreams, projects … ’ (026 – Patient)
Participant: ‘Petrolina is a very bad place to get a
job. He paid for expensive colleges and never got a
job.’ (028 – Carer)
Subtheme B: structural factors
Structural factors concern organisational, regional
and national level issues affecting patient care.
While four patients and six carers felt care was
holistic and individualised, numerous disagreed.
Participants felt there was insufficient regional in-
vestment in services addressing psychological needs
of leprosy patients.
Participant: ‘I told the doctor I felt very weak. She
did all the tests quickly, found out I was anaemic
and gave me medicines for it.’ (018 – Patient)
Participant: ‘The doctor does counselling, but there
should be a psychologist. Petrolina has to invest
more in this.’ (005 – Patient)
Six patients and two carers felt the health care sys-
tem was disorganised, consequently negatively im-
pacted their perceptions of care. Two patients noted
medication and healthcare equipment resource scar-
city in clinics, with one participant explaining that
rural clinics had an additional lack of specialised staff.
Some participants blamed this on the government’s
poor national and regional healthcare decision-
making. One carer felt that despite this, resources
were pragmatically distributed.
Participant: ‘Someone did a blood test last year. We
never heard back. The results weren’t here, so it looks
like they were lost.’ (020 – Carer)
Participant: ‘So, at my clinic, there was no health
agent, no doctor … ’ (019 – Patient)
Participant: ‘Previously it was difficult but now-
adays if one health unit doesn't have treatment, they
bring it from another unit. If I run out [of medica-
tion] and they don’t have it, I just try again the next
day.’ (003 – Carer)
Participant: ‘The medication is made abroad; I
think that is why sometimes there is a lack of medi-
cation. It depends on the government, but I don’t
think they take public health seriously in Brazil.’
(006 – Carer)
Participant: ‘It is difficult in the countryside. There
is a lack of awareness. Health care professionals
need to visit us at home because it is hard travelling
to clinics.’ (005 – Patient)
Subtheme C: support factors
HCP support was reported by all participants. This came
in the form of imparting knowledge, prescribing medica-
tion, and providing strategies to make side effects
tolerable.
Participant: ‘[The HCPs] helped me a lot. In every-
thing. In giving advice, explaining things … ’ (010 –
Patient)
Participants felt family support was ‘vital’. While
both groups recognised leprosy impacted family and
societal relationships, due to stigma, transmission
risk, and dependency, both groups also credited their
support. Patients and carers with less dialogue be-
tween them about leprosy reported less intimate, un-
reliable support provision. Conversely, open patients
who educated their carers about leprosy empowered
them to provide individualised support.
Participant: ‘Only my eldest boy works. I have an-
other boy at school. He needs me as a mother, but I
am not well.’ (019 – Patient)
Participant: My neighbour said, "Get away from
him, that disease is transmissible!". So, I isolated my-
self, but then, when his wife and children came out
to talk to me, I told them, "No, I am not infectious.".
(002 – Patient)
Support from the family and social circle came in
emotional, nutritional, psychological and financial
forms.
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Participant: ‘People asked why [the patient] didn’t
leave the house. I said that he was ashamed of his
leprosy. He had depression. So, I said, "Since you
won’t go out, I’ll invite everyone home.".’ (003 –
Carer)
Researcher: ‘What is your role in the patient's life?’
Participant: ‘Her friend, her counsellor, her helper,
her strength … ’ (025 – Carer)
Participant: ‘My sister, she pays for my water, my
light. She makes food for my house when I can’t do
it.’ (019 – Patient)
Participants in both groups used religion as another
form of psychological support.
Participant: ‘I believe he will be cured. I believe in
God and whoever believes in God has everything.
You have to have faith. There are days when he at
home is agonized, restless. I take the Bible and read
to him.’ (024 – Carer)
Theme 3: clinical factors
Clinical factors refer to a patient’s healthcare neces-
sities. This theme is subdivided into two subthemes:
‘treatment and side effects’, and ‘experiences of
diagnosis’.
Subtheme a: treatment and side effects
Twelve patients and five carers experienced medica-
tion side effects. The most frequently occurring side
effect was sunburn; due to photosensitivity reactions
associated with multidrug therapy [67]. Other com-
monly reported side effects were headache, gastro-
intestinal problems, and weakness. These side effects
reduced treatment adherence. Participants worked
with HCPs to find strategies to overcome side ef-
fects, making the medications more agreeable to
patients.
Participant: ‘It’s hot here every day, and I’m ex-
posed to the sun because I’m a farmer, so my skin
became dark because of the medication.’ (019 –
Patient)
Participant: ‘I kept vomiting when I swallowed the
pills, so the doctor gave me [dimenhydrinate*].’ (010
– Patient)
*Dimenhydrinate: an antihistamine medication used
to prevent nausea and vomiting.
Participant: ‘She became weak. They said she had
anaemia because of the medicines so the nurse gave
her ferrous sulfate.’ (025 – Carer)
Participant: ‘When you take it in the morning you
feel that nausea, right? But when you take it before
sleep, you don’t feel anything.’ (026 – Patient)
All participants commented on the long treatment
regimen and dose frequency. Many felt that being men-
tally prepared to take the medication was important in
remaining compliant. Carers encouraged patient compli-
ance. The majority either saw or felt improvement with
medication, while some, who did not, felt less motivated
to stay compliant.
Participant: ‘The treatment has so many medica-
tions, so many pills every day.’ (007 – Carer)
Participant: ‘Since the disease has a cure, you have
to try to do everything to make things better.’ (016 –
Patient)
Participant: ‘She told me she had to restart treat-
ment, and the only thing I said was, "Do it, don't
stop, continue to the end, take the steps you have to
take".’ (017 – Carer)
Participant: ‘From the second day onwards, it was
only improvement.’ (012 – Patient)
Participant: ‘I have already been treated for two
years and I still have the leprosy. Where is there re-
sult? I wanted to stop taking the medicines, but the
clinic staff said that wouldn’t be good.’ (010 –
Patient)
Subtheme B: experiences of diagnosis
10 patients recalled a delayed diagnosis. For some, this was
due to receiving initially incorrect diagnoses, which left pa-
tients ‘distressed’. For others, this was because they did not
seek HCP advice until their symptoms significantly pro-
gressed. Only four patients and three carers recalled house-
hold contact tracing. Through these responses, it became
apparent that contact tracing was not only uncommon, but,
when done, too infrequent to be effective [68].
Researcher: ‘How long after seeing the first lesion
did you wait before seeing a doctor?’
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Participant: ‘A year or so passed. I went to the doc-
tor when I became numb.’ (010 – Patient)
Participant: ‘The hospital told me it was rheuma-
tism. It got worse so I went to the clinic again. Then
they told me I had advanced leprosy. If they told me
sooner, maybe I would have suffered less.’ (004 –
Patient)
Researcher: ‘When [the patient] was diagnosed, were
you examined?’
Participant: ‘No. Not me nor my children, no one. I
didn’t think about [contact tracing] until you just
said.’ (008 – Carer)
Participant: ‘The health professionals were con-
cerned not only about me, but also my family. To
prevent the disease, right?’ (017 – Carer)
Theme 4: HCP-patient-carer relationship
This theme explores how the relationship between
HCPs, patients and carers impacted TOs.
All participants felt HCPs were vital to their care, and
recognised the importance of strong HCP-patient-carer
relationships. This relationship served as the foundation
for good communication and trust. While nine patients
and six carers felt that communication was good with
HCPs, others disagreed. The clarity of information pro-
vided by HCPs similarly received mixed reviews, leading
several to feel the medication regime was ‘complicated’.
Many reported that HCPs simply stressed the import-
ance of treatment compliance, but did not offer deeper
information.
Participant: ‘I learned a lot from the doctor. She
said there are five types of leprosy, and mine attacks
the nerves and causes me to have reactions.’ (002 –
Patient)
Participant: ‘The doctor said I have to take the
medicine every day without fail, right?’
Researcher: ‘Did they tell you about the side effects,
the reason why you need it, anything like that?’
Participant: ‘No.’ (001 – Patient)
Participant: ‘I was surprised. How come the doctor
stopped the medication if I still had a lesion? It
bothers me a lot that I stopped the treatment then.
Nobody told me exactly why.’ (019 – Patient)
Opinions were also mixed concerning the trust be-
tween HCPs and participants. Some participants sus-
pected HCPs of omitting important information during
consultations. For others, outcomes desired by patients
appeared misaligned with those desired by HCPs. The
interdependence of trust and good communication be-
comes apparent through such responses.
Participant: ‘The doctor at my clinic, I tell her
everything. My whole story of suffering, everything.’
(019 – Patient)
Participant: ‘Maybe, the doctors don’t tell me about
everything I should know.’ (006 – Carer)
Participant: ‘In the eyes of the doctors, I am better,
but my leg still feels numb, that’s the problem.’ (002
– Patient)
Most participants, however, felt comfortable sharing
worries with HCPs. A number mentioned specific staff
members who were exceptionally helpful in their care.
Participants felt valued by HCPs, and respected in the
clinical environment.
Participant: ‘I was worried about my daughter. The
doctor told me, “Look, she will live a normal life,
study, date, everything.”. I felt relieved.’ (025 –
Carer)
Participant: ‘I am always welcomed in the clinic.
All the staff take good care of patients; they are very
polite, very excellent indeed.’ (003 – Carer)
Participant: ‘The two doctors here are very good. If
the doctors are worried about your health, they will
find out what is wrong as soon as they can.’ (026 –
Patient)
Discussion
This study explored factors influencing leprosy TOs
through interviews with 27 leprosy retreatment patients
and carers. Separately analysing the two groups pro-
duced two homologous sets of four interdependent
themes: ‘personal factors’; ‘external factors’; ‘clinical fac-
tors’; and ‘the HCP-patient-carer relationship’. These
themes provide a comprehensive societal insight on
TOs, and collectively challenge current leprosy manage-
ment strategies in Pernambuco, Brazil.
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Personal factors
The study findings suggest that the psychological effects
of leprosy, health beliefs, quality and extent of know-
ledge and character impact leprosy TOs.
Both participant groups displayed poor basic know-
ledge of leprosy. Poor knowledge on the cause of leprosy
facilitated distrust in pharmaceutical medications, as this
knowledge is required to appreciate that antimicrobials
combat infection [69]. This pharmaceutical medication
distrust increased likelihood of belief in non-evidence
based, traditional medicines, which themselves have
poorer TOs [70, 71]. Poor knowledge about relapse also
fostered pharmaceutical medication distrust. Most par-
ticipants did not distinguish their/the patient’s current
treatment as a separate, second round of medication for
relapse; facilitating perceptions that the medication regi-
men is unnecessarily long, ineffective and a source of
unwanted side-effects. Poor knowledge about leprosy
transmission formed another barrier to optimal TOs; re-
ducing preventative and symptom-presenting behav-
iours [72]. Improving the study population’s basic
knowledge of leprosy and treatment may increase
pharmaceutical medication belief, and facilitate psycho-
logical coping with treatment length and side effects.
Additionally, countering false transmission beliefs with
evidence-based knowledge may dampen Pernambuco’s
‘hyperendemic’ status, by encouraging the public to: seek
contact tracing; be wary of transmission routes; and
understand how treatment compliance makes transmis-
sion improbable [73–75]. This relationship between dis-
ease knowledge and positive TOs is supported by
literature studying other diseases [27, 76–81].
HCPs were perceived as the most superior knowledge
source, effectively endorsing treatment compliance, in-
cluding in those expressing medication distrust. Future
strategies should exploit this population’s faith in HCPs
to increase leprosy TOs, by a) maximising HCP-led lep-
rosy education towards patients and carers, and b) en-
couraging HCPs to increase public health-seeking
behaviour, through sign-posting other reliable, easily ac-
cessible resources. HCP-led leprosy education could
tackle Pernambuco’s financial burden of avoidable ‘treat-
ment drop-out’ and relapse patients, as literature on
other diseases suggests this as a cost-effective method
on larger, policy-making scales [19, 82–84]. Agreeing
with previous literature, [85], ‘expert patients’ were per-
ceived as valuable supplementary knowledge source.
This study promotes using ‘expert patients’ to increase
societal leprosy awareness, and spread positive experi-
ences to patients and carers yet to witness symptomatic
improvements (a subgroup more likely to develop
pharmaceutical medication disbelief).
This study highlights leprosy’s relationship with psy-
chological wellbeing. The transition of family members
into carers altered relationship dynamics, due to changes
in physical and emotional dependency levels, intimacy
and financial support. The roles and responsibilities of
patients and carers changed, with occupation almost al-
ways impacted. This caused altered/lost identities in
both patients and carers. Psychological comorbidities,
external and self-stigma (fuelled by societal perceptions
of leprosy as ‘dangerous’ and biblical associations), and
visual symptoms (particularly in females), exacerbated
psychological distress [64]. Given the impact of mental
wellbeing on TOs, [86–88] these findings promote a psy-
chological component in leprosy treatment, led by men-
tal health specialists trained to provide individualised
care [89]. Strategies to protect psychological wellbeing,
such as mental preparation for treatment and maintain-
ing positive outlooks, could additionally be promoted by
HCPs to newly diagnosed patients and their carers, to
aid coping. Campaigns promoting leprosy as curable and
non-transmissible during treatment may reduce existing
societal stigma, further reducing leprosy’s psychological
impact [90, 91]. Executing such campaigns on mass
scales could target all pockets of society, with wide-
spread positive implications.
External factors
The study findings also indicate that socioeconomic,
structural and support factors impact leprosy TOs.
Leprosy exhibited several negative, interdepending, so-
cioeconomic consequences on patients and carers. In-
creases in disease and side effect severity made patients
increasingly dependent on carers; impacting both
groups’ abilities to maintain employment. Participants
implied that unless employment loss was compensated
for by carers adopting additional earning responsibilities,
household ability to afford rent, nutritious food, and
travel to appointments would be thwarted. Both of these
consequences decrease patient treatment engagement, as
either patient care is compromised, or patients progres-
sively lose wealth and become impoverished. This results
in a vicious cycle of increasing dependency and conse-
quent financial instability [92–97]. While Brazil’s ‘Bolsa
Familia’ conditional cash transfer programme aims to
protect from this vicious cycle, [98, 99] it is perhaps in-
adequate as income replacement; because while several
participants alluded to their household financial insecur-
ity, only one felt supported by ‘Bolsa Familia’. Partici-
pants with aspiring careers or infected children were not
immune to this vicious cycle; as stigma in occupational
and educational settings, alongside Pernambuco’s job
shortages and poverty [18, 46], impacted pursuing voca-
tional education and training. This study promotes local
financial support schemes for leprosy patients and
carers, to shield from continuous financial setbacks.
Food vouchers in other Brazilian states and direct
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income replacement in Nigeria and China have shown
promise, and could be trialled in Pernambuco [100–
102]. Superior to financial or material help, vocational
skills and disability-friendly workplaces may enable pa-
tients and carers to permanently escape this socioeco-
nomic vicious cycle, improving TOs [103].
This study exposes regional resource scarcity and
healthcare disorganisation, particularly rurally. Possibly a
direct consequence of Brazil’s geographical healthcare
inequalities, these findings underline a need for regional
and national changes in: healthcare quality standards; re-
source distribution; and public healthcare investment
[15]. The several avoidable retreatment patients in Per-
nambuco present unnecessary financial burdens to
healthcare policy makers [19]. Investing into improved
resources and holistic care may be a cost-effective long-
term solution; as the resulting improved TOs will gener-
ate smaller future expenditures on leprosy patients, and
a larger, fit-to-work, economy-contributing population
[104].
While HCP support is well recognised in wider litera-
ture, this study provides novel insight on carer roles
[105, 106]. Family members adopted carer responsibil-
ities for patients; overcoming personal stigmas and
transmission fears to provide psychological, nutritional,
and financial support. Some patients became their
carers’ personal ‘expert patient’; fostering stronger, indi-
vidualised support-giving, consequently facilitating TOs.
Although modifying patient motivation and attitude is
inherently challenging, as behavioural change is complex
and multifactorial, [107] this study shows carer-led en-
couragement increases patient psychological wellbeing
and resilience. Encouraging conversations about stigma
between patients and carers may further nurture trust-
ing, open relationships; supplementing carer-led psycho-
logical support [91]. HCPs could utilise their
trustworthiness to encourage more intimate patient-
carer dialogue. Despite leprosy’s biblical associations
fuelling self-stigma for some [64], religion provided per-
sonal support mechanisms facilitating optimal TOs for
many. Once religion is identified as a supportive source
for an individual, HCPs could further improve psycho-
logical wellbeing (and consequently TOs), by directing
patients and carers to religious congregations and wor-
ship places.
Clinical factors
This study and previous literature appreciate that treat-
ment side effects negatively impact TOs [32, 100, 108].
This study additionally supports side effect-reduction
strategies (using additional medication or modifying
medication administration times) to facilitate TOs.
Echoing previous literature findings, lengthy treatments
and medication ingestion frequency, both inflexible, also
negatively affected TOs, particularly in polypharmacy
patients [27, 32–36]. However, mental resilience and
preparedness made treatment lengths and dose fre-
quency more agreeable to patients. This is perhaps be-
cause such individuals had better medication
compliance, and consequently witnessed symptom im-
provement, which confirmed belief in treatment. This
study also found that delayed diagnosis, due to incorrect
HCP symptom recognition, poor health-seeking behav-
iours, and absent/infrequent (hence ineffective) contact
tracing, negatively affected TOs.
HCPs, as the gateway to healthcare delivery, are key to
facilitating optimal TOs clinically [34]. The study find-
ings suggest HCPs should reassure patients that strat-
egies to overcome side effects exist, promote
psychological resilience, and endorse awareness cam-
paigns like ‘Purple January’ to facilitate TOs [63]. HCP
retraining on symptom awareness, contact tracing and
evolving MRI/ultrasonography modalities may aid earlier
disease diagnosis and improved TOs, as shown in wider
literature [109, 110]. Observations from HCP retraining
workshops held at the time of the study (Fonseca A, per-
sonal communication, March 2020); alongside findings
of a simultaneously conducted study on HCP percep-
tions towards leprosy by co-author MB, indicate urgency
for better location-specific HCP retraining and patient
education [111].
HCP-patient-carer relationship
Resonating with previous literature, good patient/carer
relationships with HCPs facilitated trust, and conse-
quently improved TOs [27, 32–36]. Patients and carers
credited HCPs as ‘vital’ for care, and felt valued, wel-
comed and comfortable sharing concerns with them.
Some staff members were recognised numerous times
for their care quality. However, this study also exposes a
need for improved depth and clarity of HCP-led com-
munication. Patients practiced treatment compliance
despite HCPs providing dissatisfactory, surface-level
communication at times. This points towards paternalis-
tic medicine cultures, presenting additional TO barriers
[100, 112]. Increasing dialogue and trust between HCPs,
patients and carers, through HCP communication skills
retraining, may encourage more satisfying, individualised
care experiences [100, 112]. This study stresses the im-
portance of cultivating strong carer-HCP relationships.
Encouraging carers to attend appointments will enable
them to interpret HCP advice with patients, developing
the carer role into one of even higher quality individua-
lised care.
Strengths and limitations
This study’s primary strength is the deep insight it pro-
vides on the perceptions, experiences and beliefs of
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leprosy and treatment in Pernambuco, a ‘hyperendemic’
yet under-researched location. However, given this
study’s qualitative design, caution should be taken when
generalising findings to populations beyond those ex-
plored [113]. Additionally, the use of small participant
numbers, and exclusion of ‘treatment dropout’ patients
(due to recruitment difficulties), impact representative-
ness. This deserves appreciation before applying these
findings to similarly endemic locations [49].
As a cross-language study, translators and interpreters
impacted data collection and analysis [114]. Braun and
Clarke’s method obtains meanings from collected textual
data [56]. Therefore, interpreters and translators increase
chance of obtained meanings becoming dissimilar to
those actually expressed by participants, by being ‘lost in
translations’ [114]. Wider literature, however, suggests
that thematically analysing translated data largely does
not impact thematic synthesis [115]. Strategies reducing
bias relating to misinterpretation, involving pilot inter-
views and secondary, independent translation checks,
were undertaken regardless. LD and PR, both Brazilian
nationals, facilitated participant comfort during inter-
views, as they interviewed members of their own com-
munity; and clarified cultural references in participant
responses. DK, PR and LD were neutral and uninvolved
in patient care, however may have still evoked some
social-acceptability bias.
In retrospect, further limitations exist in the lack of
real-time translation during interviews. This would have
allowed DK to delve deeper into desired topics, particu-
larly surrounding participants’ thoughts on governmen-
tal and regional strategies for leprosy eradication, and
religious beliefs.
Finally, the impact of DK, the lead researcher (Brit-
ish Indian, female medical student), conducting this
cross-cultural investigation requires appreciation. Cul-
ture is outlined as a set of distinguishing, discriminat-
ing features of a social group [116]; therefore, as a
foreigner to this community in Petrolina, DK’s pre-
suppositions and beliefs may have biased data inter-
pretation and analysis. These effects, and therefore
researcher bias, were minimised through LD and PR
explaining cultural references, triangulation and dis-
cussions on theme formation.
Conclusion
This study identifies personal factors, external factors,
clinical factors and factors relating to the HCP-
patient-carer relationship impacting leprosy TOs. This
study contributes to location-specific, state and na-
tional levels by informing the development of higher
quality health promotion; holistic, individualised care
provision; and evenly geographically distributed finan-
cial investment into leprosy patients and the
healthcare provisions they utilise. Failure to address
these findings will hinder regional elimination efforts.
Further studies, exploring views of the ‘treatment
dropout’ subgroup and evaluating the effectiveness of
future, newly imposed interventions, may provide
additional, highly relevant evidence.
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